Health Catalyst (NASDAQ:HCAT) Stock: Insider Benjamin Landry Sells 29,478 Shares

Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) General Counsel Benjamin Landry sold 29,478 shares of the company’s stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $1.39, for a total value of $40,974.42. Following the sale, the general counsel owned 251,894 shares of the company’s stock, valued at approximately $350,132.66. This represents a 10.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Landry also recently made the following trade(s):

  • On Wednesday, November 11th, Benjamin Landry sold 70,000 shares of Health Catalyst stock. The shares were sold at an average price of $1.43, for a total value of $100,100.00.

Health Catalyst Trading Up 11.0%

Health Catalyst stock traded up $0.15 during midday trading on Friday, reaching $1.51. The company’s stock had a trading volume of 465,291 shares, compared to its average volume of 348,183. Health Catalyst, Inc. has a 52 week low of $0.96 and a 52 week high of $3.02. The business has a 50-day moving average price of $1.69 and a 200-day moving average price of $1.68. The stock has a market cap of $114.99 million, a PE ratio of -0.53 and a beta of 1.52.

Health Catalyst (NASDAQ:HCAT – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. Health Catalyst had a negative net margin of 74.24% and a negative return on equity of 4.84%. The firm had revenue of $56.28 million during the quarter, compared to analysts’ expectations of $55.39 million. As a group, research analysts predict that Health Catalyst, Inc. will post -0.18 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Citigroup lowered their price objective on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Canaccord Genuity Group lowered shares of Health Catalyst from a “buy” rating to a “hold” rating and cut their target price for the company from $3.00 to $1.80 in a research report on Thursday, August 20th. Wells Fargo & Company decreased their target price on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a research note on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Health Catalyst in a report on Monday, October 26th. Five investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Reduce” and an average price target of $2.01.

Check Out Our Latest Analysis on Health Catalyst

Institutional Trading of Health Catalyst

A number of hedge funds have recently made changes to their positions in the company. Palogic Value Management L.P. bought a new stake in shares of Health Catalyst during the second quarter worth about $9,796,000. BlackRock Inc. acquired a new position in shares of Health Catalyst in the second quarter valued at approximately $3,654,000. Marshall Wace LLP acquired a new position in shares of Health Catalyst in the third quarter valued at approximately $1,810,000. Hsbc Holdings PLC bought a new position in Health Catalyst in the 2nd quarter valued at approximately $809,000. Finally, Squarepoint Ops LLC increased its position in Health Catalyst by 1,214.8% in the 2nd quarter. Squarepoint Ops LLC now owns 400,210 shares of the company’s stock valued at $796,000 after acquiring an additional 369,772 shares during the period. 85.00% of the stock is owned by institutional investors and hedge funds.

Health Catalyst Company Profile

(Get Free Report)

Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company’s offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.

Featured Articles

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.